Ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKI-606 administered orally to healthy subjects

Trial Profile

Ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKI-606 administered orally to healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2012

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 15 Nov 2009 Results were presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
    • 13 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top